Quantum Genomics SA is a biopharmaceutical company, which engages in the development of therapies for cardiovascular diseases. It focuses on the development of drug class based on the central action mechanism of Aminopeptidase A inhibition. The company was founded by Lionel Ségard on December 23, 2005 and is headquartered in Paris, France.